Apixaban and rivaroxaban, both direct-acting oral anticoagulants, are being increasingly used in routine clinical practice because of their fixed dosing and favourable pharmacological profiles
2018
Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis
Key concepts
Scholarcy highlights
- Apixaban and rivaroxaban, both direct-acting oral anticoagulants, are being increasingly used in routine clinical practice because of their fixed dosing and favourable pharmacological profiles
- The primary effectiveness outcome was the incidence of recurrent venous thromboembolism and the primary safety outcome was the incidence of major bleeding events
- 15 254 patients were included in the cohort
- In multivariable Cox regression models, the use of apixaban compared with rivaroxaban was associated with decreased risk of recurrent venous thromboembolism and major bleeding events
- Each drug has been convincingly shown to be non-inferior to vitamin K antagonists for the prevention of recurrent venous thromboembolism or death related to venous thromboembolism, with a further reduction in major or clinically relevant bleeding
- The claims-based study by Ghadeer Dawwas and colleagues1 published in The Lancet Haematology concluded that apixaban was more effective and associated with less major bleeding than rivaroxaban in the prevention of recurrent venous thromboembolism
Need more features? Save interactive summary cards to your Scholarcy Library.